Recursion climbs as experimental drug reduces polyp growth in rare disease trial

Recursion Pharmaceuticals

08/12/2025 12:51

** Shares of drug developer Recursion Pharma RXRX.O rise 6.2% to $5.05 premarket

** Co says its experimental oral drug, REC-4881, helped reduce abnormal growths, called polyps, in the colon of patients with a rare genetic condition called familial adenomatous polyposis

** In an early to mid-stage trial, 9 out of 11 patients maintained a durable reduction in total polyp burden, 12 weeks after discontinuing therapy

** Co is looking to expand the study to a broader population of patients aged 18 years and above

** Up to last close, stock down 30.3% YTD

 (Reporting by Christy Santhosh)

 ((Christy.Santhosh@thomsonreuters.com))